country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P5462

Copy Link Print Information

PLP (180-199)

PLP (180-199) is a myelin proteolipid protein-derived peptide corresponding to amino acids 180-199 of PLP. PLP (180-199) acts as an encephalitogenic peptide and induces experimental autoimmune encephalomyelitis (EAE) in susceptible BALB/c mice. PLP (180-199) can stimulate antigen-specific T-cell responses, promote inflammatory cytokine production including IFN-γ and TNF-α, and is used for the study of autoimmune encephalomyelitis and multiple sclerosis-related immune responses.

For research use only. We do not sell to patients.

CAS No.: 165549-58-6
Formula: C₉₂H₁₄₅N₂₃O₃₀S
Molecular Weight:2085.34

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PLP (180-199) Chemical Structure

CAS No.: 165549-58-6

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All TNF Receptor Isoforms :

In Vitro

PLP (180-199) stimulates antigen-specific lymphocyte proliferation in spleen and lymph node cells isolated from PLP180-199-immunized BALB/c mice after peptide restimulation^[1].
PLP (180-199) (10 μg/mL) induces IFN-γ and TNF-α production in lymphoid cells isolated from PLP180-199-immunized BALB/c mice after peptide stimulation^[2].
PLP (180-199) (10-14 days after immunization) stimulates proliferation and IFN-γ production of spleen and lymph node cells from wild-type and B cell-deficient BALB/c mice after PLP180-199 immunization^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PLP (180-199) (200 μg/mouse; s.c.; emulsified with IFA containing 0.5 mg/mouse Mycobacterium tuberculosis H37RA; pertussis toxin 300 ng i.v. at immunization and 72 h later) induces experimental autoimmune encephalomyelitis (EAE) in female BALB/c mice after subcutaneous immunization with peptide emulsified in adjuvant, resulting in clinical paralysis and CNS inflammatory pathology^[1].
PLP (180-199) (200 μg/mouse; s.c. immunization) induces EAE in BALB/c mice with increased clinical disease scores and characteristic ascending paralysis^[2].
PLP (180-199) (200 μg/mouse; s.c. immunization) induces EAE in wild-type and B cell-deficient BALB/c mice and regulates disease severity through antigen-specific immune responses^[3].

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

1. Experimental Autoimmune Encephalomyelitis (EAE) Model^[1]^[2]^[3]

Background

PLP (180-199) peptide induces autoimmune responses against myelin proteins, activating autoreactive T cells and causing inflammatory demyelinating lesions in the central nervous system, thereby inducing EAE^[1]^[2]^[3].

Specific Modeling Methods

Mice: Female•BALB/c mice•(6-8 weeks old)
Administration: PLP (180-199) peptide (200 μg/mouse) emulsified 1:1 in incomplete Freund’s adjuvant (IFA) containing Mycobacterium tuberculosis H37Ra (0.5 mg/mouse; 0.1 mL emulsion/mouse)•administered subcutaneously (s.c.) at immunization sites. Pertussis toxin (300 ng/mouse) was injected intravenously (i.v.) at the time of immunization and 72 h later to induce EAE

Note

(1) PLP (180-199) peptide should be emulsified with incomplete Freund’s adjuvant containing Mycobacterium tuberculosis H37RA before subcutaneous immunization.
(2) Pertussis toxin administration is required for EAE induction and was given intravenously at immunization and 72 h later.
(3) Clinical EAE severity was evaluated using a clinical scoring system based on paralysis progression.

Modeling Indicators

Clinical assessment: Clinical EAE score, including ascending paralysis symptoms such as limp tail, hind limb weakness/paralysis and forelimb involvement.
Histology analysis: Inflammatory cell infiltration, demyelination, and axonal loss in the central nervous system.
Immune response analysis:Increased PLP-specific T cell responses and altered cytokine production, including IFN-γ and IL-10 changes.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 165549-58-6
Molecular Weight 2085.34
Formula C₉₂H₁₄₅N₂₃O₃₀S
Sequence

Trp-Thr-Thr-Cys-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu
Sequence Shortening

WTTCQSIAFPSKTSASIGSL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lyons JA, et al., B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice. J Autoimmun. 2008 Sep;31(2):149-55. [Content Brief]

[2]. Lyons JA, et al. Identification of the Encephalitogenic Epitopes of CNS Proteolipid Protein in BALB/c Mice. Journal of Autoimmunity. 2002;19:195–201.

[3]. Nath N, et al. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology. 2006;118:384–391.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PLP (180-199)

All TNF Receptor Isoforms